|
| Benzene Leukemia Lawsuits |
|
| |
Different Types of Acute Myelogenous Leukemia (AML) |
| |
There are different subtypes of Acute Myelogenous Leukemia (AML).
The subtypes of acute myelogenous leukemia are based on how mature (developed) the cancer cells are at the time of diagnosis and how different they are from normal cells.
| |
| Designation |
Cell Subtype |
| M0 |
Myeloblastic, on special analysis |
| M1 |
Myeloblastic, without maturation |
| M2 |
Myeloblastic, with maturation |
| M3 |
Promyeloctic |
| M4 |
Myelomonocytic |
| M5 |
Monocytic |
| M6 |
Erythroleukemia |
| M7 |
Megakaryocytic |
|
| |
"Myleoblast" is the term for an undeveloped type of white cell. If myeloblasts are the dominant leukemia cell in the marrow at the time of diagnosis, the leukemia is referred to as "myeloblastic" type. If there are many myeloblasts, but there are some cells developing towards fully formed blood cells, the added designation, "with maturation" is used. If there are cells that are developing features of monocytes ("monocytic" type) or red cells ("erythroleukemia" type), these designations are used, and so forth.
The subclassification of the disease is important. The type of therapy may differ, based on subtype and the course of the disease may be different as well.
Additional features may be important in guiding the choice of therapy, including: abnormalities of chromosomes, the cell immunophenotype, the age and the general health of the patient.
There are certain chromosomal changes that can give important information for patient management. For example, three chromosomal changes have a relatively favorable prognosis, especially in younger patients. These chromosomal changes account for between 20 to 25 percent of all cases of acute myelogenous leukemia (AML).
| |
- Acute Myelogenous Leukemia (AML) associated with a translocation between chromosomes 8 and 21(t8;21)
- Acute Myelogenous Leukemia (AML) associated with a translocation of chromosome 16 (t16;16)
- Acute Myelogenous Leukemia (AML) associated with a translocation between chromosomes 15 and 17 (t15;17)
|
| |
Acute Myelogenous Leukemia (AML) characterized by a transloacation between chromosomes 15 and 17 requires a different treatment that other types of AML. |
| |
|
|
|
|
|
|
|
| |
|
1.888.604.3438 |
|
|
|
|
|
|
